JP5972667B2 - Hyaluronic acid synthesis promoter and topical skin preparation - Google Patents

Hyaluronic acid synthesis promoter and topical skin preparation Download PDF

Info

Publication number
JP5972667B2
JP5972667B2 JP2012117866A JP2012117866A JP5972667B2 JP 5972667 B2 JP5972667 B2 JP 5972667B2 JP 2012117866 A JP2012117866 A JP 2012117866A JP 2012117866 A JP2012117866 A JP 2012117866A JP 5972667 B2 JP5972667 B2 JP 5972667B2
Authority
JP
Japan
Prior art keywords
hyaluronic acid
pomegranate juice
fermented
lactic acid
acid synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012117866A
Other languages
Japanese (ja)
Other versions
JP2013245170A (en
Inventor
大隅 和寿
和寿 大隅
浩章 足立
浩章 足立
坂井田 勉
勉 坂井田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Menard Cosmetic Co Ltd
Original Assignee
Nippon Menard Cosmetic Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Menard Cosmetic Co Ltd filed Critical Nippon Menard Cosmetic Co Ltd
Priority to JP2012117866A priority Critical patent/JP5972667B2/en
Publication of JP2013245170A publication Critical patent/JP2013245170A/en
Application granted granted Critical
Publication of JP5972667B2 publication Critical patent/JP5972667B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

本願発明は、ザクロ果汁の乳酸菌発酵物を有効成分として含有することにより、生体内のヒアルロン酸の合成能力を高める事で皮膚の老化やアトピー性皮膚炎、乾癬や魚鱗癬等の皮膚疾患、リウマチ等関節炎の予防・治療に用いることのできるヒアルロン酸合成促進剤及び皮膚外用剤に関する。   The present invention contains a fermented lactic acid bacterium of pomegranate juice as an active ingredient, thereby enhancing the ability to synthesize hyaluronic acid in the living body, skin aging, atopic dermatitis, skin diseases such as psoriasis and ichthyosis, rheumatism The present invention relates to a hyaluronic acid synthesis promoter and an external preparation for skin which can be used for prevention and treatment of isoarthritis.

従来より、皮膚中には真皮・表皮のいずれにもヒアルロン酸があることが知られている。ヒアルロン酸はグルクロン酸とN―アセチルグルコサミンが交互に結合した高分子で、その分子量は数百万にも及び、多くの水分を保持できる事が明らかとなっている。しかしながらこのヒアルロン酸は加齢と共に減少する事が報告されており(特許文献1)、これにより老化に伴う皮膚の保水力の減少を引き起こし、乾燥肌等の原因となると考えられている。また関節リウマチ患者の場合、関節中のヒアルロン酸が減少し、同様に化膿性関節炎や通風性関節炎等でもヒアルロン酸含量の低下が起こることから、それらの症状を改善するためにヒアルロン酸合成促進剤が有効であることが記載されている(特許文献2、特許文献3)。 Conventionally, it is known that hyaluronic acid is present in the dermis and epidermis in the skin. Hyaluronic acid is a polymer in which glucuronic acid and N-acetylglucosamine are alternately bonded, and has a molecular weight of several millions, and it has been revealed that it can retain a large amount of water. However, it has been reported that this hyaluronic acid decreases with aging (Patent Document 1), which causes a decrease in the water retention capacity of the skin accompanying aging, and is considered to cause dry skin and the like. In patients with rheumatoid arthritis, hyaluronic acid in the joints decreases and hyaluronic acid content decreases in purulent arthritis and ventilated arthritis. Is described as being effective (Patent Documents 2 and 3).

ザクロには、エラグ酸等の抗酸化成分が含まれ、抗老化作用が期待できること、また、女性ホルモン様成分が含まれ、美容と健康に対する効果が期待できることから、その花、果実、種子等が健康食品や化粧品原料として利用されている。その主要な特許文献としては、抗酸化作用を有する化粧品(特許文献4)、美白作用を有する化粧品(特許文献5)、抗アレルギー作用(ヒアルロニダーゼ阻害作用)を有する皮膚外用剤(特許文献6)、女性ホルモン様作用を有する化粧品(特許文献7)、エラスターゼ阻害剤(特許文献8)、炎症性サイトカインの合成抑制剤(特許文献9)が挙げられる。しかしながら、生体内のヒアルロン酸の合成能力を高める効果については、記載されていない。   Pomegranate contains antioxidant components such as ellagic acid and can be expected to have an anti-aging effect, and it contains female hormone-like components that can be expected to have an effect on beauty and health. Used as a health food and cosmetic ingredient. The main patent documents include cosmetics having an antioxidant action (Patent Document 4), cosmetics having a whitening action (Patent Document 5), skin external preparations having an anti-allergic action (hyaluronidase inhibitory action) (Patent Document 6), Examples include cosmetics having a female hormone-like action (Patent Document 7), elastase inhibitors (Patent Document 8), and inhibitors for the synthesis of inflammatory cytokines (Patent Document 9). However, there is no description on the effect of increasing the synthesis ability of hyaluronic acid in vivo.

なお、ザクロ果汁の乳酸菌による発酵物の利用は、ザクロ果汁の酸度が高く発酵性が悪いことからあまり利用されていない。果汁の乳酸菌発酵物を有効成分とする美容剤に関する特許文献(特許文献10)には、果汁の乳酸菌発酵物の美容剤に関する記載があるが、ザクロ果汁に関する具体的な有効性に関する記載はない。また、特許文献(特許文献11)には、乳酸菌ラクトバチルス・プランタラムのヒドロキシペルオキシドとリノール酸ヒドロキシペルオキシドに対する分解特性を示す抗酸化剤に関して記載されている。しかしながら、乳酸菌発酵に用いる具体的な対象物について、及び抗酸化作用以外の効果にについては記載されていない。
また、ザクロ果汁又はその乳酸菌発酵物のヒアルロン酸合成促進効果についての先行文献はなく、また、ザクロ果汁の乳酸菌発酵物を含有する皮膚外用剤に関する文献情報もない。
In addition, the utilization of the fermented product of the pomegranate juice by lactic acid bacteria is not so much used because the pomegranate juice has high acidity and poor fermentability. The patent document (Patent Document 10) relating to a cosmetic agent containing a lactic acid bacteria fermented product of fruit juice as an active ingredient has a description of the cosmetic agent of the lactic acid bacteria fermented product of fruit juice, but there is no description regarding specific effectiveness related to pomegranate juice. In addition, Patent Document (Patent Document 11) describes an antioxidant that exhibits degradation characteristics of lactic acid bacteria Lactobacillus plantarum to hydroxyperoxide and linoleic acid hydroxyperoxide. However, there is no description about specific objects used for lactic acid bacteria fermentation and effects other than the antioxidant action.
Moreover, there is no prior literature on the hyaluronic acid synthesis promoting effect of pomegranate juice or its lactic acid bacteria fermentation product, and there is no literature information on a skin external preparation containing the lactic acid bacteria fermentation product of pomegranate juice.

特開平10−182402JP-A-10-182402 特開2002−363081JP-A-2002-363081 特開2004−51579JP 2004-51579 A 特開平05−320037JP 05-320037 A 特開平05−331041JP 05-331041 A 特開平09−110710JP 09-110710 A 特開2001−131053JP2001-131053 特開2005−53873JP-A-2005-53873 特開2005−89304JP 2005-89304 A 特開2006−8566JP 2006-8666 A 特開2006−291146JP 2006-291146 A

かかる状況に鑑み、本願発明の課題は、天然で安全性の高い素材を用いて、より効果の高いヒアルロン酸合成促進剤を提供することにある。 In view of such a situation, an object of the present invention is to provide a hyaluronic acid synthesis accelerator having a higher effect by using a natural and safe material.

食習慣のある果汁又はそれらの発酵物についてヒアルロン酸合成促進作用を検討した。本願発明者らは、上記課題の解決に向けて鋭意検討を行った結果、ザクロ果汁にヒアルロン酸合成を促進する効果を見出した。その中で、さらに果汁の乳酸菌発酵物についても検討を行ったが、本願発明に用いたザクロ果汁については、乳酸菌による効率的な発酵方法が検討課題であった。さらに鋭意検討を行った結果、ヒアルロン酸合成を促進する効果は、ザクロ果汁の乳酸菌発酵物にのみ、偶然にも向上することを見出し、本願発明を完成するに至った。   The hyaluronic acid synthesis promoting effect was examined on fruit juices or their fermented products. As a result of intensive studies aimed at solving the above problems, the present inventors have found an effect of promoting hyaluronic acid synthesis in pomegranate juice. Among them, the lactic acid bacteria fermented product of fruit juice was also examined. However, for the pomegranate fruit juice used in the present invention, an efficient fermentation method using lactic acid bacteria was an issue to be studied. As a result of further intensive studies, it has been found that the effect of promoting hyaluronic acid synthesis is improved only by the lactic acid bacteria fermented product of pomegranate juice, and the present invention has been completed.

本願発明に用いるザクロ果汁とは、ザクロ(Punica granatum)の果汁である。果汁は、市販のザクロから、圧搾により絞ることが可能であるが、業務用に流通しているザクロ果汁の濃縮物を利用することができる。果汁は、そのまま用いても良く、又は濃縮果汁を用いてもよく、また希釈して用いても良い。また、発酵を効率的にするため、水酸化ナトリウム等のアルカリでpHを3〜8に調整して用いても良い。また、乳酸桿菌の生育促進を目的として、酵母エキスや大豆ペプチド等の有機物、硫酸マグネシウム等のミネラルを添加しても良い。   The pomegranate juice used in the present invention is pomegranate (Punica granatum) juice. The fruit juice can be squeezed from commercially available pomegranate by pressing, but a concentrate of pomegranate fruit juice distributed for business use can be used. The fruit juice may be used as it is, or concentrated fruit juice may be used, or it may be diluted. Moreover, in order to make fermentation efficient, you may adjust and adjust pH to 3-8 with alkalis, such as sodium hydroxide. For the purpose of promoting the growth of lactobacilli, organic substances such as yeast extract and soybean peptide, and minerals such as magnesium sulfate may be added.

本願発明に用いる乳酸菌としては、例えば、ラクトバチルス属(Lactobacillus)、ラクトコッカス属(Lactococcus)、ロイコノストック属(Leuconostoc)、又はペディオコッカス属(Pediococcus)に属する乳酸菌が挙げられる。好ましくは、発酵による有効性向上の点でラクトバチルス・プランタラム(Lactobacillus plantarum)に属する乳酸菌であって、植物、又はその発酵食品である漬け物等から分離した菌株であっても、菌株保存機関に登録されたものであっても良い。また、ザクロ果汁をpH3〜5の範囲で効率よく発酵させ得るものが好ましい。   Examples of lactic acid bacteria used in the present invention include lactic acid bacteria belonging to the genus Lactobacillus, the genus Lactococcus, the genus Leuconostoc, or the genus Pediococcus. Preferably, even if it is a lactic acid bacterium belonging to Lactobacillus plantarum in terms of improving the effectiveness by fermentation and is isolated from a plant or pickled food that is a fermented food thereof, It may be registered. Moreover, what can ferment pomegranate juice efficiently in the range of pH 3-5 is preferable.

培養条件としては、適宜設定できる。例えば、培養温度は、特に限定されるものではないが、目安として15〜45℃あり、25〜40℃が良い。   Culture conditions can be set as appropriate. For example, the culture temperature is not particularly limited, but is 15 to 45 ° C. as a guide, and 25 to 40 ° C. is preferable.

ザクロ果汁又はその乳酸菌発酵物は、そのまま用いても良く、必要に応じて、抽出、濃縮、稀釈、ろ過等の処理及び活性炭等による脱色、脱臭処理をして用いても良い。抽出する溶媒としては、水、エタノール、1,3−ブチレングリコール、又はその混合液でも良く、抽出温度は室温でも加熱しても良い。   The pomegranate juice or its lactic acid bacteria fermented product may be used as it is, and may be used after treatment such as extraction, concentration, dilution, filtration, and decolorization or deodorization with activated carbon or the like. The solvent to be extracted may be water, ethanol, 1,3-butylene glycol, or a mixture thereof, and the extraction temperature may be heated at room temperature.

本願発明のヒアルロン酸合成促進剤又は皮膚外用剤への配合は、上記抽出物をそのまま使用しても良く、抽出物の効果を損なわない範囲内で、化粧品、医薬部外品、医薬品又は食品等に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、金属石鹸、pH調整剤、防腐剤、香料、保湿剤、粉体、紫外線吸収剤、増粘剤、色素、酸化防止剤、美白剤、キレート剤、賦形剤、皮膜剤、甘味料、酸味料等の成分を配合することもできる。   In the formulation of the hyaluronic acid synthesis promoter or skin external preparation of the present invention, the above extract may be used as it is, and within the range not impairing the effect of the extract, cosmetics, quasi drugs, pharmaceuticals, foods, etc. Fats and oils, waxes, hydrocarbons, fatty acids, alcohols, esters, surfactants, metal soaps, pH adjusters, preservatives, perfumes, moisturizers, powders, UV absorbers Ingredients such as thickeners, pigments, antioxidants, whitening agents, chelating agents, excipients, film agents, sweeteners, acidulants can also be blended.

本願発明のヒアルロン酸合成促進剤又は皮膚外用剤の剤型としては、例えば、化粧水、クリーム、マッサージクリーム、乳液、ゲル剤、エアゾール剤、パック、洗浄剤、浴用剤、ファンデーション、打粉、口紅、軟膏、パップ剤、ペースト剤、プラスター剤、エッセンス、散剤、丸剤、錠剤、注射剤、坐剤、乳剤、カプセル剤、顆粒剤、液剤(チンキ剤、流エキス剤、酒精剤、懸濁剤、リモナーデ剤等を含む)、錠菓、飲料等が挙げられる。   Examples of the dosage form of the hyaluronic acid synthesis accelerator or skin external preparation of the present invention include, for example, lotion, cream, massage cream, emulsion, gel, aerosol, pack, cleaning agent, bath preparation, foundation, dusting, lipstick, Ointment, cataplasm, paste, plaster, essence, powder, pill, tablet, injection, suppository, emulsion, capsule, granule, liquid (tincture, fluid extract, spirits, suspension, Limonade agents, etc.), tablet confectionery, beverages and the like.

本願発明のヒアルロン酸合成促進剤又は皮膚外用剤において、ザクロ果汁及びその乳酸菌発酵物の含有量は特に限定されないが、固形分として30%以下であることが好ましく、0.001〜10重量%含まれる濃度で使用することが最も好ましい。0.0001重量%未満であると本願発明の効果が十分に発揮されにくい場合がある。   In the hyaluronic acid synthesis promoter or skin external preparation of the present invention, the content of pomegranate juice and its fermented lactic acid bacteria is not particularly limited, but is preferably 30% or less as a solid content, and 0.001 to 10% by weight Most preferably, it is used at a concentration that can be used. If it is less than 0.0001% by weight, the effect of the present invention may not be sufficiently exerted.

本願発明に用いるザクロ果汁は、天然で安全性の高い素材であり、優れたヒアルロン酸合成促進効果を認めた。また、その乳酸菌発酵物は、発酵前よりさらにヒアルロン酸合成促進効果が増大することから、皮膚の老化やアトピー性皮膚炎、乾癬や魚鱗癬等の皮膚疾患、リウマチ等関節炎の予防・治療に効果が期待でき、医薬品、医薬部外品、化粧品、食品等への配合や応用が可能である。   The pomegranate juice used in the present invention is a natural and highly safe material, and has an excellent hyaluronic acid synthesis promoting effect. In addition, the fermented product of lactic acid bacteria has an effect of further promoting hyaluronic acid synthesis before fermentation, so it is effective in preventing and treating skin aging, atopic dermatitis, skin diseases such as psoriasis and ichthyosis, and arthritis such as rheumatism. Therefore, it can be formulated and applied to pharmaceuticals, quasi-drugs, cosmetics, foods, and the like.

本願発明に用いるザクロ果汁及びその乳酸菌発酵物は、優れたヒアルロン酸合成促進効果を有しており、医薬品、医薬部外品、化粧品、食品の分野において利用できるものである。さらに、ザクロ果汁を特定の条件で発酵すると、上記効果が向上する。   The pomegranate juice used in the present invention and its fermented lactic acid bacteria have an excellent hyaluronic acid synthesis promoting effect and can be used in the fields of pharmaceuticals, quasi drugs, cosmetics, and foods. Furthermore, when the pomegranate juice is fermented under specific conditions, the above effect is improved.

次に本願発明を詳細に説明するため、実施例として本願発明に用いる乳酸菌発酵物の製造例、処方例及び実験例を挙げるが、本願発明はこれに限定されるものではない。実施例に示す配合量の部とは重量部を、%とは重量%を示す。
以下に、ザクロ果汁の乳酸菌発酵物の製造例を示す。
Next, in order to describe the present invention in detail, examples of production, formulation examples and experimental examples of fermented lactic acid bacteria used in the present invention will be given as examples, but the present invention is not limited thereto. In the examples, the part of the amount is part by weight, and% is% by weight.
Below, the manufacture example of the lactic acid bacteria fermented product of a pomegranate fruit juice is shown.

製造例1 ザクロ果汁の発酵物
濃縮ザクロ果汁(Brix65)を、水で希釈してBrix15に調整し、水酸化ナトリウム水溶液を用いてpH5に調整した。調整液500gにラクトバチルス・プランタラムに属する乳酸菌(漬物由来)の種菌を加えた。30℃にて2日間発酵してろ過し、ザクロ果汁の発酵物450gを得た。
Production Example 1 Fermented Pomegranate Juice Concentrated pomegranate juice (Brix65) was diluted with water to adjust to Brix15, and adjusted to pH 5 using an aqueous sodium hydroxide solution. An inoculum of lactic acid bacteria (derived from pickles) belonging to Lactobacillus plantarum was added to 500 g of the adjustment liquid. Fermented at 30 ° C. for 2 days and filtered to obtain 450 g of a pomegranate juice fermented product.

製造例2 ザクロ果汁の発酵物
濃縮ザクロ果汁(Brix65)を、水で希釈してBrix11に調整し、水酸化ナトリウム水溶液を用いてpH4.5に調整した。調整液500gにラクトバチルス・プランタラムに属する乳酸菌(漬物由来)の種菌を加えた。30℃にて2日間発酵してろ過し、ザクロ果汁の発酵物450gを得た。
Production Example 2 Fermented Pomegranate Juice Concentrated pomegranate juice (Brix65) was diluted with water to adjust to Brix11, and adjusted to pH 4.5 using an aqueous sodium hydroxide solution. An inoculum of lactic acid bacteria (derived from pickles) belonging to Lactobacillus plantarum was added to 500 g of the adjustment liquid. Fermented at 30 ° C. for 2 days and filtered to obtain 450 g of a pomegranate juice fermented product.

製造例3 ザクロ果汁の発酵物
濃縮ザクロ果汁(Brix65)を、水で希釈してBrix8に調整し、水酸化ナトリウム水溶液を用いてpH4.5に調整した。調整液500gにラクトバチルス・プランタラムに属する乳酸菌(漬物由来)の種菌を加えた。30℃にて2日間発酵してろ過し、ザクロ果汁の発酵物450gを得た。
Production Example 3 Fermented Pomegranate Juice Concentrated pomegranate juice (Brix65) was diluted with water to adjust to Brix8, and adjusted to pH 4.5 using an aqueous sodium hydroxide solution. An inoculum of lactic acid bacteria (derived from pickles) belonging to Lactobacillus plantarum was added to 500 g of the adjustment liquid. Fermented at 30 ° C. for 2 days and filtered to obtain 450 g of a pomegranate juice fermented product.

製造例4 ザクロ果汁の発酵物
ザクロ果汁を、水酸化ナトリウム水溶液を用いてpH4.5に調整した。調整液500gにラクトバチルス・プランタラムに属する乳酸菌(漬物由来)の種菌を加えた。30℃にて2日間発酵してろ過し、ザクロ果汁の発酵物450gを得た。
Production Example 4 Pomegranate juice fermented product Pomegranate juice was adjusted to pH 4.5 using an aqueous sodium hydroxide solution. An inoculum of lactic acid bacteria (derived from pickles) belonging to Lactobacillus plantarum was added to 500 g of the adjustment liquid. Fermented at 30 ° C. for 2 days and filtered to obtain 450 g of a pomegranate juice fermented product.

製造例5 ザクロ果汁の発酵物
製造例2のザクロ果汁の発酵物210gに1,3−ブチレングリコール90gを加えてろ過し、ザクロ果汁の発酵物280gを得た。
Production Example 5 Fermented Pomegranate Juice 90 g of 1,3-butylene glycol was added to 210 g of the pomegranate juice fermented in Production Example 2 and filtered to obtain 280 g of a pomegranate juice fermented product.

製造例6 ザクロ果汁の発酵物の凍結乾燥物
製造例1のザクロ果汁の発酵物100gについて、凍結乾燥し、ザクロ果汁の発酵物の凍結乾燥物15gを得た。
Production Example 6 Lyophilized Product of Fermented Pomegranate Juice 100 g of the fermented pomegranate juice of Production Example 1 was freeze-dried to obtain 15 g of a freeze-dried pomegranate juice fermented product.

製造例7 ザクロ果汁の発酵物の凍結乾燥物
製造例3のザクロ果汁の発酵物100gについて、凍結乾燥し、ザクロ果汁の発酵物の凍結乾燥物8gを得た。
Production Example 7 Lyophilized product of fermented pomegranate juice 100 g of the fermented pomegranate juice of Production Example 3 was freeze-dried to obtain 8 g of a freeze-dried pomegranate juice fermented product.

製造例8 ザクロ果汁の発酵物の乾燥物
製造例4のザクロ果汁の発酵物200gに120gのデキストリンを加え、スプレードライヤーにて乾燥し、ザクロ果汁の発酵物の乾燥物145gを得た。
Production Example 8 Dry Product of Pomegranate Juice Fermented Product 120 g dextrin was added to 200 g of the pomegranate juice fermented product of Production Example 4 and dried with a spray dryer to obtain 145 g of a dried product of pomegranate juice.

以下に、ザクロ果汁又はその乳酸菌発酵物を用いたヒアルロン酸合成促進剤及び皮膚外用剤の処方例を示す。   Below, the formulation example of the hyaluronic acid synthesis promoter using the pomegranate fruit juice or its lactic acid bacteria fermented product and a skin external preparation is shown.

処方例1 化粧水
成分 配合量(部)
1.ザクロ果汁の発酵物(製造例5) 5.0
2.1,3−ブチレングリコール 8.0
3.グリセリン 2.0
4.キサンタンガム 0.02
5.クエン酸 0.01
6.クエン酸ナトリウム 0.1
7.エタノール 5.0
8.パラオキシ安息香酸メチル 0.1
9.ポリオキシエチレン硬化ヒマシ油(40E.O.) 0.1
10.香料 適量
11.精製水にて全量を100とする
[製造方法]成分1〜6及び11と、成分7〜10をそれぞれ均一に溶解し、両者を混合しろ過して製品とする。
Formulation Example 1 Lotion Ingredient Ingredients (parts)
1. Fermented pomegranate juice (Production Example 5) 5.0
2. 1,3-butylene glycol 8.0
3. Glycerin 2.0
4). Xanthan gum 0.02
5. Citric acid 0.01
6). Sodium citrate 0.1
7). Ethanol 5.0
8). Methyl paraoxybenzoate 0.1
9. Polyoxyethylene hydrogenated castor oil (40E.O.) 0.1
10. Perfume proper amount11. [Manufacturing method] Components 1 to 6 and 11 and components 7 to 10 are uniformly dissolved in purified water, and both are mixed and filtered to obtain a product.

比較例1 従来の化粧水
処方例1において、ザクロ果汁の発酵物(製造例5)を精製水に置き換えたものを従来の化粧水とした。
Comparative Example 1 Conventional Lotion A conventional lotion was obtained by replacing the fermented pomegranate juice (Production Example 5) with purified water in Formulation Example 1.

処方例2 クリーム
成分 配合量(部)
1.ザクロ果汁の発酵物(製造例5) 0.5
2.スクワラン 5.5
3.オリーブ油 3.0
4.ステアリン酸 2.0
5.ミツロウ 2.0
6.ミリスチン酸オクチルドデシル 3.5
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ベヘニルアルコール 1.5
9.モノステアリン酸グリセリン 2.5
10.香料 0.1
11.パラオキシ安息香酸メチル 0.2
12.パラオキシ安息香酸エチル 0.05
13.1,3−ブチレングリコール 8.5
14.精製水にて全量を100とする
[製造方法]成分2〜9を加熱溶解して混合し、70℃に保ち油相とする。成分1及び11〜14を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分10を加え、更に30℃まで冷却して製品とする。
Formulation Example 2 Cream Ingredients Amount (parts)
1. Fermented pomegranate juice (Production Example 5) 0.5
2. Squalane 5.5
3. Olive oil 3.0
4). Stearic acid 2.0
5. Beeswax 2.0
6). Octyldodecyl myristate 3.5
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Behenyl alcohol 1.5
9. Glycerol monostearate2.5
10. Fragrance 0.1
11. Methyl paraoxybenzoate 0.2
12 Ethyl paraoxybenzoate 0.05
13.1,3-Butylene glycol 8.5
14 [Manufacturing method] Components 2 to 9 are heated and dissolved and mixed with purified water to a total amount of 100, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 11 to 14 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 10 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.

処方例3 ゲル剤
成分 配合量(部)
1.ザクロ果汁(発酵前) 5.0
2.エタノール 5.0
3.パラオキシ安息香酸メチル 0.1
4.ポリオキシエチレン硬化ヒマシ油(60E.O.) 0.1
5.香料 適量
6.1,3−ブチレングリコール 5.0
7.グリセリン 5.0
8.キサンタンガム 0.1
9.カルボキシビニルポリマー 0.2
10.水酸化カリウム 0.2
11.精製水にて全量を100とする
[製造方法]成分2〜5と、成分1及び6〜11をそれぞれ均一に溶解し、両者を混合して製品とする。
Formulation Example 3 Gel Agent Ingredient Amount (parts)
1. Pomegranate juice (before fermentation) 5.0
2. Ethanol 5.0
3. Methyl paraoxybenzoate 0.1
4). Polyoxyethylene hydrogenated castor oil (60 EO) 0.1
5. Perfume appropriate amount 6.1,3-butylene glycol 5.0
7). Glycerin 5.0
8). Xanthan gum 0.1
9. Carboxyvinyl polymer 0.2
10. Potassium hydroxide 0.2
11. [Production method] Ingredients 2 to 5 and ingredients 1 and 6 to 11 are uniformly dissolved in purified water, and the two are mixed to obtain a product.

処方例4 浴用剤
成分 配合量(部)
1.ザクロ果汁の発酵物の凍結乾燥物(製造例6) 1.0
2.炭酸水素ナトリウム 50.0
3.黄色202号(1) 適量
4.香料 適量
5.硫酸ナトリウムにて全量を100とする
[製造方法]成分1〜5を均一に混合し製品とする。
Formulation Example 4 Bath agent Ingredients Amount (parts)
1. Lyophilized product of fermented pomegranate juice (Production Example 6) 1.0
2. Sodium bicarbonate 50.0
3. Yellow No. 202 (1) Appropriate amount 4. Perfume appropriate amount 5. [Manufacturing method] Ingredients 1 to 5 are mixed uniformly with sodium sulfate to make a product.

処方例5 錠剤
成分 配合量(部)
1.ザクロ果汁の発酵物の凍結乾燥物(製造例7) 5.0
2.乾燥コーンスターチ 25.0
3.カルボキシメチルセルロースカルシウム 20.0
4.微結晶セルロース 40.0
5.ポリビニルピロリドン 7.0
6.タルク 3.0
[製造方法]成分1〜4を混合し、次いで成分5の水溶液を結合剤として加えて顆粒成型する。成型した顆粒に成分6を加えて打錠する。1錠0.52gとする。
Formulation Example 5 Tablet Ingredient Amount (parts)
1. Lyophilized product of fermented pomegranate juice (Production Example 7) 5.0
2. Dried corn starch 25.0
3. Carboxymethylcellulose calcium 20.0
4). Microcrystalline cellulose 40.0
5. Polyvinylpyrrolidone 7.0
6). Talc 3.0
[Production method] Components 1 to 4 are mixed, and then an aqueous solution of component 5 is added as a binder to form granules. Ingredient 6 is added to the molded granules and compressed. One tablet is 0.52 g.

処方例6 錠菓
成分 配合量(部)
1.ザクロ果汁の発酵物の乾燥物(製造例8) 2.0
2.乾燥コーンスターチ 49.8
3.エリスリトール 40.0
4.クエン酸 5.0
5.ショ糖脂肪酸エステル 3.0
6.香料 0.1
7.精製水 0.1
[製造方法]成分1〜4及び7を混合し、顆粒成型する。成型した顆粒に成分5及び6を加えて打錠する。1粒1.0gとする。
[製造方法]成分1及び2を加えて混合する。
Formulation Example 6 Tablet Confectionery Ingredients Amount (parts)
1. Dry product of fermented pomegranate juice (Production Example 8) 2.0
2. Dried corn starch 49.8
3. Erythritol 40.0
4). Citric acid 5.0
5. Sucrose fatty acid ester 3.0
6). Fragrance 0.1
7). Purified water 0.1
[Production method] Components 1 to 4 and 7 are mixed and granulated. Ingredients 5 and 6 are added to the molded granules and tableted. One tablet is 1.0 g.
[Production Method] Components 1 and 2 are added and mixed.

次に、本願発明の効果を詳細に説明するため、実験例を挙げる。   Next, in order to explain the effect of the present invention in detail, an experimental example is given.

実験例1 ヒアルロン酸合成促進試験
正常ヒト皮膚線維芽細胞におけるヒアルロン酸合成促進効果を、ヒアルロン酸合成酵素−2(HAS−2)mRNAの発現量を指標として評価した。HAS−2は、細胞膜に存在するヒアルロン酸を合成する酵素の1つである。
Experimental Example 1 Hyaluronic Acid Synthesis Promotion Test The hyaluronic acid synthesis promoting effect in normal human skin fibroblasts was evaluated using the expression level of hyaluronic acid synthase-2 (HAS-2) mRNA as an index. HAS-2 is one of the enzymes that synthesize hyaluronic acid present in the cell membrane.

正常ヒト皮膚線維芽細胞を6cmシャーレに播種し、コンフルエントな状態になった後、固形分として0.01mg/ml濃度の試料を添加した培地(1%FBSを含むDMEM)にてさらに24時間培養し、総RNAを抽出した。総RNAの抽出には、TRIzol Reagent(インビトロジェン)を用いた。細胞から抽出した総RNAを基に、RT−PCR法によりHAS−2のmRNA発現量の測定を行った。RT−PCR法にはSuperscript3 Platinum Two−Step qRT−PCR Kit with SYBR Green(インビトロジェン)を用いた。PCR反応は、95℃−2分の初期変性を行った後、95℃−15秒、60℃−31秒を1サイクルとして40サイクル行った。また、内部標準としては、β−アクチンを用いた。その他の操作は、定められた方法に従い、HAS−2 mRNAの発現量を、内部標準であるβ−アクチンmRNA発現量に対する割合として求めた。コントロールに対する試料添加時のHAS−2 mRNA発現量の割合を算出し、ヒアルロン酸合成促進率とした。尚、測定に使用したプライマーは以下の通りである。   Normal human skin fibroblasts are seeded in a 6 cm petri dish and become confluent, and further cultured in a medium (DMEM containing 1% FBS) supplemented with a 0.01 mg / ml concentration sample as a solid content. And total RNA was extracted. TRIzol Reagent (Invitrogen) was used for extraction of total RNA. Based on the total RNA extracted from the cells, the expression level of HAS-2 mRNA was measured by RT-PCR. For the RT-PCR method, Superscript 3 Platinum Two-Step qRT-PCR Kit with SYBR Green (Invitrogen) was used. The PCR reaction was carried out for 40 cycles, with initial denaturation at 95 ° C. for 2 minutes followed by 95 ° C. for 15 seconds and 60 ° C. for 31 seconds. Further, β-actin was used as an internal standard. For other operations, the expression level of HAS-2 mRNA was determined as a ratio relative to the expression level of β-actin mRNA, which is an internal standard, according to a predetermined method. The ratio of HAS-2 mRNA expression level at the time of sample addition relative to the control was calculated and used as the hyaluronic acid synthesis acceleration rate. The primers used for the measurement are as follows.

HAS−2用のプライマーセット
TGGATGACCTACGAAGCGATTA(配列番号1)
GCTGGATTACTGTGGCAATGAG(配列番号2)
Primer set TGGATGACCCTACGAAGCGATTA for HAS-2 (SEQ ID NO: 1)
GCTGGATTACTGTGGCAATGAG (SEQ ID NO: 2)

β−アクチン用のプライマーセット
CACTCTTCCAGCCTTCCTTCC(配列番号3)
GTGTTGGCGTACAGGTCTTTG(配列番号4)
Primer set CACTCTCCCAGCCTCTCTCCC for β-actin (SEQ ID NO: 3)
GTGTTGCGCGTACAGGTCTTTG (SEQ ID NO: 4)

これらの試験結果を表1に示した。発酵前、発酵後(製造例1)共にヒアルロン酸合成促進効果が認められたが、発酵物(製造例1)は、発酵前と比較して、より強くなった。同様に製造例2〜4の発酵物についても強いヒアルロン酸合成促進効果が認められた。なお、このような乳酸菌による発酵に伴うヒアルロン酸合成促進効果の向上については、ザクロ果汁以外では認められなかった。   The test results are shown in Table 1. Although the hyaluronic acid synthesis promoting effect was recognized both before fermentation and after fermentation (Production Example 1), the fermented product (Production Example 1) became stronger than before fermentation. Similarly, a strong hyaluronic acid synthesis promoting effect was observed for the fermented products of Production Examples 2 to 4. In addition, about the improvement of the hyaluronic acid synthesis promotion effect accompanying such fermentation by lactic acid bacteria, it was not recognized except pomegranate juice.

Figure 0005972667
Figure 0005972667

実験例2 使用試験
処方例1の化粧水及び比較例1の従来の化粧水を用いて、小じわや肌のハリに悩む女性15人(23〜50才)を対象に1ヶ月間の使用試験を行った。使用後、小じわや肌のハリについてのアンケート調査を行った。
Experimental example 2 Use test Using the lotion of prescription example 1 and the conventional lotion of comparative example 1, a use test for one month was conducted for 15 women (23 to 50 years old) suffering from fine lines and skin firmness. went. After use, we conducted a questionnaire survey on fine lines and skin firmness.

アンケート調査の結果を表2に示した。本願発明のザクロ果汁の発酵物を含有する皮膚外用剤は、優れた小じわ、肌のハリの改善作用を示した。なお、試験期間中、皮膚トラブルは一人もなく、安全性においても問題なかった。また、処方成分の劣化についても問題なかった。   The results of the questionnaire survey are shown in Table 2. The external preparation for skin containing the fermented pomegranate juice of the present invention showed an excellent effect of improving fine wrinkles and skin firmness. During the test period, there was no skin problem and there was no problem with safety. There was also no problem with the deterioration of the prescription ingredients.

Figure 0005972667
Figure 0005972667

本願発明は、生体内のヒアルロン酸の合成能力を高める事で皮膚の老化やアトピー性皮膚炎、乾癬や魚鱗癬等の皮膚疾患、リウマチ等関節炎の予防・治療に用いることのできるヒアルロン酸合成促進剤及び皮膚外用剤を提供できる。   The invention of the present application promotes hyaluronic acid synthesis that can be used for prevention and treatment of skin aging, atopic dermatitis, skin diseases such as psoriasis and ichthyosis, and arthritis such as rheumatoid arthritis by enhancing the ability to synthesize hyaluronic acid in vivo. Agent and external preparation for skin can be provided.

Claims (4)

ザクロ果汁の乳酸菌発酵物を含有することを特徴とするヒアルロン酸合成促進剤(皮膚外用剤及び浴用剤を除く)A hyaluronic acid synthesis promoter (excluding external preparations for skin and bath preparations) characterized by containing a lactic acid bacteria fermentation product of pomegranate juice. 乳酸菌がラクトバチルス・プランタラムであることを特徴とする請求項記載のヒアルロン酸合成促進剤。 Hyaluronic acid synthesis promoting agent according to claim 1, wherein the lactic acid bacterium is Lactobacillus plantarum. ザクロ果汁のラクトバチルス・プランタラムによる乳酸菌発酵物を含有することを特徴とする関節炎の予防又は改善剤。A prophylactic or ameliorating agent for arthritis, comprising a lactic acid bacteria fermentation product of pomegranate juice Lactobacillus plantarum. ザクロ果汁のラクトバチルス・プランタラムによる乳酸菌発酵物を含有することを特徴とする化膿性関節炎又は通風性関節炎の予防又は改善剤。A preventive or ameliorating agent for purulent arthritis or ventilated arthritis characterized by containing a lactic acid bacteria fermentation product of Lactobacillus plantarum of pomegranate juice.

JP2012117866A 2012-05-23 2012-05-23 Hyaluronic acid synthesis promoter and topical skin preparation Active JP5972667B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012117866A JP5972667B2 (en) 2012-05-23 2012-05-23 Hyaluronic acid synthesis promoter and topical skin preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012117866A JP5972667B2 (en) 2012-05-23 2012-05-23 Hyaluronic acid synthesis promoter and topical skin preparation

Publications (2)

Publication Number Publication Date
JP2013245170A JP2013245170A (en) 2013-12-09
JP5972667B2 true JP5972667B2 (en) 2016-08-17

Family

ID=49845226

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012117866A Active JP5972667B2 (en) 2012-05-23 2012-05-23 Hyaluronic acid synthesis promoter and topical skin preparation

Country Status (1)

Country Link
JP (1) JP5972667B2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6281905B2 (en) * 2014-03-05 2018-02-21 日本メナード化粧品株式会社 Square plug formation inhibitor
KR20160011536A (en) * 2014-07-22 2016-02-01 (주) 건강사랑 Composition for improving skin condition comprising pomegranate concentrate as active ingredient
JP2017014154A (en) * 2015-07-01 2017-01-19 公立大学法人岡山県立大学 Hyaluronic acid production promoter containing urolithins
KR101908976B1 (en) * 2017-01-09 2018-10-17 주식회사 아미코스메틱 A cosmetic composition containing lactobacillus-fermented extract for improving atopic dermatitis
WO2019045037A1 (en) * 2017-09-01 2019-03-07 ハウスウェルネスフーズ株式会社 Composition for promoting production of hyaluronic acid
CN107988115B (en) * 2017-12-27 2020-06-23 北京科拓恒通生物技术股份有限公司 Lactobacillus plantarum and composite probiotic fermentation liquor and preparation method thereof
KR101927826B1 (en) * 2018-10-29 2018-12-11 주식회사 에이치엘사이언스 Composition for improving skin condition comprising pomegranate concentrate as active ingredient
KR101933152B1 (en) * 2018-12-03 2018-12-27 주식회사 에이치엘사이언스 Composition for improving skin condition comprising pomegranate concentrate as active ingredient
KR20200136729A (en) * 2019-05-28 2020-12-08 서울대학교산학협력단 Pharmaceutical composition for preventing or treating atopic dermatitis comprising bio-fermented papaya

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH069371A (en) * 1992-06-23 1994-01-18 Mikimoto Pharmaceut Co Ltd Hyaluronidase inhibitor
JPH07196526A (en) * 1994-01-11 1995-08-01 Takano Co Ltd Inhibitor of collagenase
JP2000247896A (en) * 1999-02-26 2000-09-12 Snow Brand Milk Prod Co Ltd Bone quantity reduction-inhibitory composition
JP2001131053A (en) * 1999-11-08 2001-05-15 Ryokusei Mes Kk Cosmetic utilizing pomegranate component
JP3785424B2 (en) * 2001-10-05 2006-06-14 上地 俊徳 Pomegranate Lactic Acid Fermented Beverage
DE10231468A1 (en) * 2002-07-08 2004-02-26 Coty B.V. Anti-Hautalterungskosmetikum
JP2005047817A (en) * 2003-07-29 2005-02-24 Nonogawa Shoji Kk Arthritis-preventing or improving agent
JP2005089304A (en) * 2003-09-12 2005-04-07 Nippon Menaade Keshohin Kk Production inhibitor of inflammatory cytokine
JP2006008566A (en) * 2004-06-24 2006-01-12 Ichimaru Pharcos Co Ltd Cosmetic agent containing lactic acid bacteria fermentation product of fruit juice as active ingredient and its application
KR101456052B1 (en) * 2007-04-20 2014-11-03 주식회사 엘지생활건강 Anti-wrinkle cosmetic composition

Also Published As

Publication number Publication date
JP2013245170A (en) 2013-12-09

Similar Documents

Publication Publication Date Title
JP5972667B2 (en) Hyaluronic acid synthesis promoter and topical skin preparation
JP6884608B2 (en) Compositions and external preparations for skin
JP6670166B2 (en) Cosmetics
TWI668009B (en) Skin external agent for skin whitening comprising an extract of fermented wheat germ
JP6969067B2 (en) Anti-inflammatory, anti-aging and whitening agents
JP2021502953A (en) Cosmetic composition for skin whitening and wrinkle improvement containing Centella asiatica extract as an active ingredient
JP2015157773A (en) cosmetic
JPWO2018123828A1 (en) Fermented product and method for producing the same
JP2022078231A (en) Skin external preparations
JP2016193857A (en) Skin cosmetic, and food and drink
KR101532001B1 (en) Cosmetics comprising fermented materials for preventing or improving skin wrinkle
CN114262667A (en) Novel aureobasidium pullulans strain and application thereof
KR102365655B1 (en) Composition for preventing or improving skin wrinkle containing Glycine max Merrill fermented extract
JP4054730B2 (en) α-Glucosidase activator
KR20110121775A (en) Cosmetic composition comprising the extract of thalictrum rochebrunianum as active ingredient
KR101775485B1 (en) Cosmetic composition containing fermentative extract of Spatholobus suberectus Dunn as active ingredient
JP2024500509A (en) Novel Saccharomyces cerevisiae strains and their uses
JP7148115B2 (en) Collagen production promoter, MMP inhibitor, melanogenesis inhibitor, cell proliferation promoter, antioxidant, wrinkle improving agent, pharmaceutical or food composition
KR20110122448A (en) Cosmetic composition comprising the extract of filipendula formosa as active ingredient
KR101008954B1 (en) a cosmetic composition, a pharmaceutical composition comprising fermented product from acai berry and a method for fermentating acai berry
KR20160122379A (en) Manufacture method of fermented complex using dongchimi materials and cosmetic composition using by the method and cosmetic comprising the cosmetic composition
KR102532713B1 (en) Novel Saccharomyces cerevisiae strain and use thereof
JP7433628B2 (en) Skin external preparations and internal preparations
JP7330475B2 (en) Oral composition and external skin composition
JP2018008903A (en) Weight-reducing composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150306

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160713

R150 Certificate of patent or registration of utility model

Ref document number: 5972667

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250